Partex NV and Fortress Biotech (FBIO) announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence for potential acquisition or licensing by Fortress. “Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers diverse recommendations on alternative targets or indications and helps search and evaluate compounds across therapeutic areas. Partex’s platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative therapeutics faster to market,” the companies stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO:
- Fortress Biotech, Partex enter collaboration for asset identification, evaluatio
- Biotech Alert: Searches spiking for these stocks today
- Fortress Biotech price target raised to $16 from $15 at Roth MKM
- Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
- Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex